TIANJIN, China Oct. 29, 2004 LAWFUEL – Law, law firm, legal, attorney news–Genex Pharmaceutical, Inc. (OTCBB:GENX; website: www.genexpharm.com), a Delaware corporation, is a profitable biomedical technology company with a revolutionary product for treating various bone-related injuries called Reconstituted Bone Xenograft (RBX), which is a medical device approved by the SFDA (Chinese State Food and Drug Administration). RBX is suitable for compound or complex bone fractures, compression fractures and intractable fractures, bone defects, vertebral column or joint rehabilitation and for bone absence after tumor removal such as a bone cyst.
The Company announces that it has engaged the law firm of Holland & Knight (www.hklaw.com), a leading law firm with practice groups and industry-based teams comprised of more than 1200 lawyers and professionals worldwide to advise the Company as its SEC counsel. In addition, the Company has engaged Weinberg & Company, Inc. as its independent auditors.
Mr. Fuzhi Song, Chairman and CEO of Genex, stated, “As a public company, we are pleased to work with these highly qualified professionals to help us improve our business and potentially increase our visibility and credibility in the investment community. We appreciate the services that have been provided to us by our previous law firm and auditors. We look forward to releasing strong third quarter financial results ending September 30 in the near future.”
Genex Pharmaceutical’s RBX is well suited to treat numerous bone-related injuries. Industry statistics estimate that over 15 million people in China suffer from some sort of bone defect, and the Company’s RBX product is targeted to this potentially huge market. Other applications of RBX include treatment of dental decay, from which approximately 40 million people every year in China require treatment.
About Genex Pharmaceutical, Inc.
Genex Pharmaceutical, Inc. is a biomedical technology company with distinctive proprietary technology for an orthopedic device that treats bone-related injuries. Headquartered in Tianjin, China, the Company manufactures and distributes Reconstituted Bone Xenograft (RBX), to 400 hospitals in 22 provinces throughout mainland China. RBX is approved by the State Food and Drug Administration (SFDA) in China (the Chinese government agency that regulates drugs and medical devices). RBX offers a modern alternative to traditional methods of treating orthopedic injuries.
Safe Harbor Statement
Statements about the Company’s future expectations, including future revenue and earnings and all other statements in this press release, other than historical facts, are “forward-looking” statements and are made pursuant to safe harbor provisions of the Securities Exchange Act of 1934. Such forward-looking statements involve risks and uncertainties and are subject to change at any time. The Company’s actual results could differ materially from expected results. In reflecting subsequent events or circumstances, the Company undertakes no obligation to update forward-looking statements.
Genex Pharmaceutical, Inc.
Fuzhi Song, 86-22-23370770